16th September 2021
Director/PDMR Shareholding
Nuformix plc (LSE: NFX), a pharmaceutical development company targeting unmet…
News
13th September 2021
Worldwide licensing agreement with Oxilio for NXP001
Nuformix plc (LSE: NFX), a pharmaceutical development company targeting…
24th August 2021
Results of Annual General Meeting
Nuformix plc (LSE: NFX), a pharmaceutical development company targeting unmet…
23rd July 2021
Posting of Annual Report and Notice of AGM
Nuformix plc (LSE: NFX), a pharmaceutical development company targeting unmet…
22nd July 2021
Letter to shareholders re: Dr Anne Brindley – (Reach – non-regulatory announcement)
Nuformix plc (LSE: NFX), a pharmaceutical development company targeting unmet…
21st July 2021
Directorate change
Nuformix plc (LSE: NFX), a pharmaceutical development company targeting unmet…
15th July 2021
Final results for the year ended 31 March 2021
Nuformix plc (LSE:NFX), a pharmaceutical development company targeting unmet…
10th June 2021
Notification of Major Holdings
TR-1: Standard form for notification of major holdings…
7th June 2021
Notice of Allowance of Patent in US
Nuformix plc (LSE: NFX), a pharmaceutical development company targeting unmet…
1st June 2021
Project update – Progress on pipeline assets NXP002 and NXP004
Nuformix plc (LSE: NFX), a pharmaceutical development company targeting unmet…
24th May 2021
Directorate Changes
Nuformix plc (LSE: NFX), a pharmaceutical development company targeting unmet…
12th May 2021
Notification of Major Shareholding
TR-1: Standard form for notification of major holdings…
11th May 2021
Notification of major shareholding
TR-1: Standard form for notification of major holdings…
8th April 2021
Notification of Major Shareholding
TR-1: Standard form for notification of major holdings…
6th April 2021
Notification of Major Shareholding
TR-1: Standard form for notification of major holdings…
30th March 2021
Notification of major shareholding
TR-1: Standard form for notification of major holdings…
29th March 2021
Result of General Meeting and Total Voting Rights
London, UK – 29 March 2021: Nuformix plc (LSE:NFX), a pharmaceutical…
22nd March 2021
NXP001 (Oncology) – Exercise of Option by Oxilio
London, UK – 22 March 2021: Nuformix plc (LSE:NFX), a pharmaceutical…
11th March 2021
Initiation of research by Allenby Capital (RNS Reach announcement)
Cambridge, UK – 11 March 2021: Nuformix plc (LSE:NFX), a pharmaceutical…
10th March 2021
Proposed placing
Cambridge, UK – 10 March 2021: Nuformix plc (LSE:NFX), a pharmaceutical…
8th March 2021
Notification of major shareholding
NTR-1: Standard form for notification of major holdings…
2nd March 2021
Nuformix Reports Results from Preliminary Preclinical Study for NXP002 (inhaled tranilast) in an ex-vivo model of IPF
Cambridge, UK – 2 March 2021: Nuformix plc (LSE:NFX), a pharmaceutical…
22nd February 2021
Notification of Major Shareholding
NTR-1: Standard form for notification of major holdings…
10th February 2021
Directorate Change
Cambridge, UK – 10 February 2021: Nuformix plc (LSE:NFX), announces that…
22nd December 2020
Interim Results for the six months ended 30 September 2020
Cambridge, UK – 22 December 2020: Nuformix plc (LSE:NFX), a drug…
22nd December 2020
Appointment of Broker
22nd December 2020: Nuformix plc (LSE:NFX), a drug re-purposing specialist,…
7th December 2020
Appointment of Chief Executive Officer – Dr Anne Brindley to start with immediate effect
Cambridge, UK – 7 December 2020: Nuformix plc (LSE:NFX; “Nuformix”, the…
2nd December 2020
Appointment of Madeleine “Maddy” Kennedy as Non-Executive Director
Cambridge, UK – 2 December 2020: Nuformix plc (LSE:NFX; “Nuformix”, the…
24th November 2020
Appointment of Dr Julian Gilbert as Non-Executive Director
Cambridge, UK – 24 November 2020: Nuformix plc (LSE:NFX; “Nuformix”, the…
26th October 2020
Notification of Major Shareholding
TR-1: Standard form for notification of major holdings 26 October…
22nd October 2020
Notification of Major Shareholding
TR-1: Standard form for notification of major holdings 22 October…
22nd October 2020
Notification of Major Shareholding
TR-1: Standard form for notification of major holdings 22 October…
7th October 2020
Placing and Strategic Update
Cambridge, UK – 7 October 2020: Nuformix plc (LSE:NFX), a drug…
24th September 2020
Exclusive Option Agreement for NXP001 in Oncology
Cambridge, UK – 24 September 2020: Nuformix plc (LSE:NFX) (“Nuformix” or…
20th August 2020
Result of Annual General Meeting held on 20 August 2020
19th August 2020
Nuformix Reports Results from Pre-clinical Pilot Study in IPF for NXP004 Programme
Cambridge, UK – 19 August 2020: Nuformix plc (LSE:NFX) (“Nuformix” or…
28th July 2020
Annual Report and Accounts for the year ended 31 March 2020 and Notice of Annual General Meeting 2020
Cambridge, UK – 28 July 2020: Nuformix plc (LSE:NFX) (“Nuformix”…
22nd July 2020
Preliminary Results for the year ended 31 March 2020
Nuformix plc (LSE:NFX) (“Nuformix” or “the Group”), a pharmaceutical development…
1st July 2020
Notification of Major Shareholding
Notification of Major Shareholding…
22nd June 2020
Board Change
Nuformix announces the resignation of Dr. Dan Gooding, Chief Executive…
27th May 2020
Nuformix and VistaGen Announce CNS Agreement
Nuformix plc (LSE:NFX) (“Nuformix” or “the Company”), the pharmaceutical development…
27th May 2020
Business Update
Nuformix, the pharmaceutical development company focused on unlocking the therapeutic…
6th May 2020
Notification Major Share Interests
Nuformix, the pharmaceutical development company using cocrystal technology to unlock…
3rd April 2020
Notification Major Share Interests
Nuformix, the pharmaceutical development company using cocrystal technology to unlock…
30th March 2020
Notiication of Major Share Holding
Nuformix, the pharmaceutical development company using cocrystal technology to unlock…
18th February 2020
Appointment of Dr Karl Keegan
Nuformix, the pharmaceutical development company using cocrystal technology to unlock…
12th February 2020
Notification Major Share Interests
Nuformix, the pharmaceutical development company using cocrystal technology to unlock…
5th February 2020
Operational Update
Nuformix, the pharmaceutical development company using cocrystal technology to unlock…
5th February 2020
Resignation of Dave Tapolczay
Nuformix, the pharmaceutical development company using cocrystal technology to unlock…
5th February 2020
Director Dealing
Nuformix, the pharmaceutical development company using cocrystal technology to unlock…
5th February 2020
Notification Major Share Interests
Nuformix, the pharmaceutical development company using cocrystal technology to unlock…
27th January 2020
Notification Major Share Interests
Nuformix, the pharmaceutical development company using cocrystal technology to unlock…
27th January 2020
Resignation of John Lidgey
Nuformix, the pharmaceutical development company using cocrystal technology to unlock…
15th January 2020
Amendement to Notice
On 10 January 2020, the Group announced the receipt of…
10th January 2020
Issue of Equity
Nuformix, the pharmaceutical development company using cocrystal technology to unlock…
8th January 2020
Notification Major Share Interests
Nuformix, the pharmaceutical development company using cocrystal technology to unlock…
24th December 2019
Unaudited Half Year Results
Nuformix (LSE: NFX), the pharmaceutical development Group using cocrystal technology…
25th November 2019
Update and Placing Announcement
Nuformix, the pharmaceutical development company using cocrystal technology to unlock…
28th October 2019
Share Listing Anouncement
Following the receipt of Notice of Conversion of Loan Note…
25th October 2019
Statement re. Share Price Movement
Nuformix, the pharmaceutical development company using cocrystal technology to unlock…